Fintel reports that on November 13, 2024, TD Cowen downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) from ...

Fintel reports that on November 13, 2024, Brookline Capital downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS ...

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from JMP Securities analyst Jason Butler today.

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The company’s shares closed yesterday at $2.73. Nadeau covers the ...

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

Syros Pharmaceuticals Inc (NASDAQ:SYRS) is advancing tamibarotene as a potential new standard of care for higher-risk MDS patients with RARA overexpression, targeting a significant unmet medical need.

An alleged cop killer in Chicago was pictured apparently foaming at the mouth in a mugshot released by authorities on Wednesday. Darion McMillian, 23, was charged with two counts of first-degree ...

Syros Pharmaceuticals ( (SYRS)) has released its Q3 earnings. Here is a breakdown of the information Syros Pharmaceuticals presented to its investors. Syros Pharmaceuticals, Inc., a ...

California authorities have released a pair of new mugshots of the Menendez brothers as they've crossed a major threshold in their effort to have their sentences of life imprisonment without ...

Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Note that this call is being ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company focused on developing treatments for cancer and blood disorders, has been navigating a complex landscape of clinical trials ...